Pasadena-based Materia, a firm developing catalysts, said Monday that it has licensed its metathesis platform to Aileron Therapeutics for use in its biopharmaceutical research. The deal calls for Materia to receive license fees, milestone payments, and royalties. Value of the deal was not disclosed. Materia is developing catalysts that can be used to synthesize biophamaceutical products, based on olefin metathesis catalyst technology.
Top NewsTuesday, February 13, 2007
Materia Licenses Products To Aileron Therapeutics